Cite

HARVARD Citation

    Liu, B. et al. (n.d.). CX-2043, an EpCAM-targeting probody drug conjugate, demonstrates anti-tumor activity with a favorable safety profile in preclinical models. European journal of cancer. pp. S15-. [Online]. 
  
Back to record